Aurinia Pharmaceuticals (AUPH) Total Liabilities (2016 - 2026)

Aurinia Pharmaceuticals has reported Total Liabilities for 11 years, with the latest figure at $156.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 1.11% year-over-year to $156.4 million; the trailing twelve-month figure through Mar 2026 stood at $156.4 million (up 1.11% YoY), and the FY2025 full-year result was $170.3 million, down 1.68% from the prior year.
• Total Liabilities for Q1 2026 stood at $156.4 million, down from $170.3 million in the prior quarter.
• The five-year high for Total Liabilities was $173.2 million in Q4 2024, with the low at $58.4 million in Q2 2022.
• Historically, Total Liabilities has averaged $132.9 million across 5 years, with a median of $157.2 million in 2024.
• Annual changes were most pronounced in 2023 — Total Liabilities soared 168.26% — and 2025, when it slipped 1.68%.
• Aurinia Pharmaceuticals' Total Liabilities stood at $65.4 million in 2022, then jumped by 160.0% to $170.1 million in 2023, then grew by 1.8% to $173.2 million in 2024, then dropped by 1.68% to $170.3 million in 2025, then fell by 8.16% to $156.4 million in 2026.
• The last three Total Liabilities figures came in at $156.4 million (Q1 2026), $170.3 million (Q4 2025), and $161.8 million (Q3 2025), per Business Quant data.